Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

Press Release CIBC Innovation Banking announced today that it has provided credit facilities to support MediSpend's acquisition of Real Life Sciences ("RLS"), a leading provider of advanced ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas, ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

Has Gilead Sciences (GILD) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Gilead Sciences is a member of the Medical sector.

Take a spin through the latest in Gilead’s science and innovation in our new series, The Centrifuge Sessions. Today we sit down with D. Barry Crittenden, Executive Director of Clinical Development, to ...